New clinical data for ANKTIVA immunotherapy in lung cancer, a study on EBV-driven resistance via ADAR1 RNA editing, and research on microbiome metabolites modulating immunotherapy response were presented at major conferences and in recent publications.
New ASCO guideline emphasizes biomarker-driven treatment for advanced gastroesophageal cancer, recommending upfront testing for HER2, PD-L1, MSI/MMR, and CLDN18.2 to guide immunotherapy and targeted therapy selection.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07776340 |
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07775040 |
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07763171 |
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma |
NOT_YET_RECRUITING | PHASE3 |
| NCT07746141 |
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations |
NOT_YET_RECRUITING | PHASE1 |
| NCT07739186 |
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07733180 |
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07729592 |
Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome |
NOT_YET_RECRUITING | PHASE2 |
| NCT07715396 |
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden |
NOT_YET_RECRUITING | PHASE3 |
| NCT07700667 |
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07694765 |
A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
